Polyphor is focused on developing innovative drugs based on its proprietary macrocycle technologies with the aim of helping patients with an unmet medical need. The company’s growing pipeline of macrocycles targets a broad range of therapeutic areas, such as hematopoietic stem cell transplantation, leukemia, pseudomonas infections, cystic fibrosis, alpha-1 antitrypsin deficiency and chronic obstructive pulmonary disease.